Global Network = High Impact

REMAP-CAP and REMAP-COVID are collaborative efforts made possible by a network of global partners. High-impact relationships accelerate results for the world’s most urgent need – helping patients suffering from COVID-19.

The Global Coalition for Adaptive Research (GCAR) is the U.S. sponsor of the REMAP-COVID clinical trial. UPMC serves as the US Regional Coordinating Center. Special acknowledgement to the Breast Cancer Research Foundation for their support. See a full list of REMAP-CAP partners here.



Your Support is Critically Needed Now

20 x

SARS-CoV-2 (the COVID-19-causing virus) binds 10-20x more tightly to human cells than SARS-CoV (the virus responsible for SARS)

65 +

The greatest percentage of those who die from COVID-19 are age 65+ and living with a chronic disease

80 %

About 80% of COVID-19 infections are mild or asymptomatic, 15% result in moderate to severe symptoms and 5% are critical